Published : 27 Jan 2014
An Oregon drug Development Company with innovative technology licensed from Portland State University, is developing two antimalarial drugs and one antibacterial. Today they have requested Aagami again to support their partnering needs with Indian Pharmaceutical companies.
In the last assignment ( in 2012), Aagami took them to 6 qualified and interested companies. As an outcome of those meetings, it was decided that the company would need further development on their programs before partnering/out-licensing. The Oregon company is now ready with their programs to go to the clinic within this year, and based on their trust and previous experience, requested Aagami to team up for partnering with Indian companies again, including the newer companies.
They understand the strength of Indian Pharmaceuticals companies for their development capabilities and also appreciate their market reach in the regions most afflicted by Malaria. Several large Indian companies have extensive portfolio of such Anti-Malarial drugs and some of them supply majority of global needs of particular molecules.
The company has a novel approach, modifying a drug that has lost effectiveness due to drug-resistance by covalently bonding it to a molecule that overcomes the resistance. This results in new patentable drugs that are potent in animals, safe and cost effective.
Aagami team is excited by this development and is committed to put its best efforts for bringing success to its client, who has displayed such great trust and respect on Aagami again.